Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India

Puri, Raman; Mehta, Vimal; Duell, P. Barton; Wangnoo, SK; Rastogi, Ashu; Mohan, Viswanathan; Zargar, Abdul Hamid; Kalra, Sanjay; Sahoo, Abhay Kumar; Iyengar, S. S.; Yusuf, Jamal; Mukhopadhyay, Saibal; Singla, Monika; Shaikh, Altamash; Kohli, Sunil; Mathur, Sandeep Kumar; Jain, Sandeep; Narasingan, S N; Gupta, Vipul; Agarwala, Rajeev; Mittal, Vikas; Varma, Amit H.; Panda, Jayant K.; Shetty, Sadanand; Yadav, Madhur; Muruganathan, A; Dabla, Pradeep Kumar; Pareek, K K; Manoria, PC; Nanda, Rashmi; Sattur, GB; Pancholia, A K; Wong, Nathan D.

doi:10.1016/j.jacl.2022.11.002

Cited by 9 publications

(7 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid Association of India (LAI) has published consensus statements guided by an expert panel to adapt the Western guidelines to Indians. 33 , 34 , 35 , 36 The LAI guidelines have also focused on non-HDL cholesterol as a more valuable index of CAD risk in Indians and have recommended using non-HDL cholesterol as a co-primary target along with the primary target of LDL cholesterol lowering by statins. The present guidelines, supplement and complement the LAI consensus statement.…”

Section: The First Stepsmentioning

confidence: 99%

Indian dyslipidaemia guidelines: Need of the hour

Sawhney,

Gupta

2024

Indian Heart Journal

View full text Add to dashboard Cite

Section: The First Stepsmentioning

confidence: 99%

Indian dyslipidaemia guidelines: Need of the hour

Sawhney,

Gupta

2024

Indian Heart Journal

View full text Add to dashboard Cite

“…Glycation-induced abnormalities in lipoprotein function further exacerbate dyslipidemia in diabetes. Despite achieving target LDL-C (low-density lipoprotein-cholesterol) levels, diabetes independently elevates cardiovascular event risk, necessitating comprehensive management of dyslipidemia alongside glycemic control [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…This highlights the urgency for early diagnosis and targeted treatment. Indian patients with T2DM often exhibit unique characteristics compared to Western populations, including earlier onset, a higher prevalence of metabolic syndrome features, and a more aggressive course of atherosclerotic cardiovascular disease (ASCVD) complications [3]. The distinct phenotype of the Indian population, characterized by elevated body fat mass despite normal weight or body mass index (BMI), underscores their predisposition to insulin resistance, dyslipidemia, and increased risk of T2DM [4].…”

Section: Introductionmentioning

confidence: 99%

“…Despite having a mean BMI within the obese range, nearly half of non-diabetic Indians exhibit dyslipidemia, with notably higher rates of atherogenic small, dense low-density lipoprotein (LDL) particles compared to their counterparts in the United States. Furthermore, the risk of coronary artery disease (CAD) among Indians is considerably higher, necessitating aggressive interventions to mitigate ASCVD risk factors [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chronomedicine Insights: Evaluating the Impact of Time-Restricted Meal Intake on Lipid Profile Parameters Among Individuals With Type 2 Diabetes in Northern India

Rastogi,

Verma,

Raghuwanshi

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction: Time-restricted meal intake (TRM) has shown potential benefits such as enhanced insulin sensitivity, lowered blood sugar levels, and possible weight loss in individuals with type 2 diabetes mellitus (T2DM). Our study aimed to investigate the impact of TRM on lipid profile parameters such as total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL) in fasting conditions in T2DM patients. Methods: In total, 400 patients from the endocrinology department at King George's Medical University (KGMU), Lucknow were enrolled in this study, adhering to the guidelines of the American Diabetes Association (ADA). Male and female patients with recently diagnosed T2DM (in the past five years), aged between 25 to 60 years, on oral anti-diabetic therapy excluding insulin, expressing willingness to provide written consent and to adhere to TRM were included in the TRM group. It was a longitudinal study as diabetic dyslipidemia is primarily caused by insulin resistance and nutritional reasons and we wanted to assess the effect of TRM on lipid profile in T2DM patients. Patients were enrolled via simple random sampling using the random number table method (computerized). The TRM group had an early dinner at 7 pm whereas the control group was of non-TRM/late-night eaters. TRM group was given comprehensive guidance including strategies to manage hunger, permissible beverage options (water and prescribed medication) during the fasting period, and daily maintenance of a diary documenting their timing, type, and quantity of food intake which they were requested to bring fortnightly. Emphasis was placed on recording even minor dietary items consumed throughout the day. The TRM group consumed food ad libitum during a 12-hour eating window from breakfast at 7 am to dinner at 7 pm. Data distribution was non-parametric. Mann-Whitney U test compared TRM and control group using mean values at baseline and follow-ups. Analysis used GraphPad Prism 9.2.0 software (GraphPad Inc., La Jolla, CA). A p-value less than 0.05 (p < 0.05) was considered statistically significant. Results: A total of 127 patients were lost to follow-up, resulting in 273 patients who completed the study. The mean value of TC in the TRM and non-TRM groups using the Mann-Whitney U test registered a highly significant p-value <0.0001 at 18 months, with a decrease of 14.17% from baseline in the TRM group and a decrease of 1.53% from baseline in the non-TRM group. The TRM group had a decrease of 24.75% in TG from a baseline value of 145.4±41.9, whereas the non-TRM group showed a decrease of 2.2% from a baseline value of 154.7±37.30 (p-value <0.0001). The TRM group showed an increase of 9.25% in HDL from a baseline value of 50.14±8.58; the non-TRM group showed an increase of 0.82% from a baseline value of 48.62±9.31 (p-value <0.0001). TRM group showed a decrease of 8.62% in LDL from a baseline value of 68.20±16.2 while the non-TRM group showed an increase...

show abstract

“…In India, there is a remarkably high prevalence of dyslipidemia among individuals with diabetes, with recorded rates of 85.5% among males and 97.8% among females. (5) The complex interrelationship between diabetes and diabetes dyslipidemia that leads to Atherosclerotic Cardiovascular Disease (ASCVD) encompasses a range of pathologies affecting the heart and vasculatures, most notably atherosclerosis, which has the potential to obstruct blood circulation to vital organs such as the heart and brain, culminating in events such as myocardial infarctions, cerebral infarctions, and aneurysm formations. (6) Atherogenic Dyslipidemia in Diabetes (ADD) is characterized by high serum triglycerides, elevated small dense LDL levels, low HDL levels, in a person with type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

Impact of Saroglitazar as an add-on therapy to rosuvastatin in patients with diabetic dyslipidemia: A prospective, single centre, observational study in Indian patients

Anil Batta,

Sumesh Prasad Sah

2024

Open Access Res. J. Sci. Technol.

View full text Add to dashboard Cite

Background: Diabetic dyslipidemia in type 2 diabetes mellitus is defined by elevated TG levels and decreased HDL-C levels, as well as elevated or normal LDL-C levels. In diabetic dyslipidemia, the addition of saroglitazar to statins may provide comprehensive control of lipid parameters as well as good glycemic control, particularly in patients with high TG levels that are not controlled by statins alone. Objective: To evaluate the effectiveness and safety profile of saroglitazar as an add-on therapy in patients with diabetic dyslipidemia already receiving rosuvastatin therapy. Methods: In this open-label, prospective, single-center, observational study, newly diagnosed DM patients were randomly assigned to one of two groups, Rosuvastatin only (R) or Rosuvastatin plus Saroglitazar (RS). Both groups received rosuvastatin for 12 weeks, after which group R received the same treatment for another 12 weeks, and group RS received saroglitazar 4mg in addition to rosuvastatin for another 12 weeks. At the end of 24 weeks, the primary outcome measured were changes in baseline lipid parameters total cholesterol, serum TG, LDL, VLDL, HDL, and glycemic parameter HbA1c between and within Group R and Group RS. Secondary outcomes included changes in metabolic parameters such as blood urea, serum creatinine, SGOT, SGPT, and CPK, as well as reported adverse events. These assessments were made for both Group R and Group RS at both the 12-week and 24-week. Result: When compared to Group R, patients in Group RS improved significantly in lipid parameters such as total cholesterol, serum TG, LDL, VLDL, HDL, and glycemic parameter HbA1c at the end of 24 weeks. Secondary outcomes revealed that Group RS had no significant side effects when compared to Group R, as evidenced by low fluctuations in renal and hepatic markers such as B. urea, S. Creatinine, SGOT, SGPT, and CPK levels over 24 weeks. As a result, the safety profiles of the combination treatment and rosuvastatin alone were comparable. Conclusion: Saroglitazar, when combined with rosuvastatin, was found to improve lipid and glycemic parameters in diabetic dyslipidemia patients who were already on rosuvastatin.

show abstract

Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India

Cited by 9 publications

References 75 publications

Indian dyslipidaemia guidelines: Need of the hour

Indian dyslipidaemia guidelines: Need of the hour

Chronomedicine Insights: Evaluating the Impact of Time-Restricted Meal Intake on Lipid Profile Parameters Among Individuals With Type 2 Diabetes in Northern India

Impact of Saroglitazar as an add-on therapy to rosuvastatin in patients with diabetic dyslipidemia: A prospective, single centre, observational study in Indian patients

Contact Info

Product

Resources

About